Table 1 |
|
|
Therapy for rheumatoid arthritis: unmet needs |
|
|
Problem |
Details |
|
|
|
|
Heterogeneity of the disease |
Some patients respond to DMARD monotherapy |
|
Not every patient responds to anti-TNF (mono or combination) therapy |
|
|
'Remission' rates |
|
|
What is the pathology/biologic process in each individual patient? |
|
|
Toxicities |
Infections, immunogenecity, congestive heart failure, drug-induced vasculitis, etc |
|
Costs |
Limits availability to may patients |
|
|
|
|
DMARD, disease-modifying antirheumatic drug; TNF, tumor necrosis factor. |
|
|
Moreland Arthritis Research & Therapy 2005 7(Suppl 3):S2 doi:10.1186/ar1736 |
|